Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HINT1 | P49773 | 6/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314536 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL3422978 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL278167 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL1120690 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL1061031 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL25407962 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL13462039 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL14144174 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL13296251 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL16809000 | 0.95 | ALDH1A1 (0.63) | ALDH1A1LMNATP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537135-B1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7385051-B2 | Fluorescent N2,N3-etheno-purine (2′-deoxy) riboside derivatives and uses thereof | BAR-LLAN UNIVERSITY (IL) | 2008-06-10 | — | — | US | disclosed |
| US-7385051-B2 | Fluorescent N2,N3-etheno-purine (2′-deoxy) riboside derivatives and uses thereof | BAR-LLAN UNIVERSITY (IL) | 2008-06-10 | — | — | US | disclosed |
| US-6914053-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1537135-A2 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040121978-A1 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004022573-A2 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121978-A1 | Adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | ALDH1A1 811/4885LMNA 2972/4885TP53 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.